Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 169

1.

A new monoclonal antibody (CAL2) detects CALRETICULIN mutations in formalin-fixed and paraffin embedded bone marrow biopsies.

Stein H, Bob R, Dürkop H, Erck C, Kämpfe D, Kvasnicka HM, Martens H, Roth A, Streubel A.

Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.192. [Epub ahead of print]

PMID:
26202929
2.

Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA.

Leuk Lymphoma. 2015 Jul;56(7):1938-48. doi: 10.3109/10428194.2014.974594. Epub 2014 Nov 19.

PMID:
25330439
3.

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A.

Cancer Immunol Res. 2014 Aug;2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198. Epub 2014 Apr 21.

4.

Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification.

Barbui T, Thiele J, Kvasnicka HM, Carobbio A, Vannucchi AM, Tefferi A.

Leukemia. 2014 Oct;28(10):2092-4. doi: 10.1038/leu.2014.175. Epub 2014 Jun 3. No abstract available.

PMID:
24888272
5.

Netrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases.

Harter PN, Zinke J, Scholz A, Tichy J, Zachskorn C, Kvasnicka HM, Goeppert B, Delloye-Bourgeois C, Hattingen E, Senft C, Steinbach JP, Plate KH, Mehlen P, Schulte D, Mittelbronn M.

PLoS One. 2014 Mar 19;9(3):e92311. doi: 10.1371/journal.pone.0092311. eCollection 2014.

6.

Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia.

Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, Müllauer L, Kvasnicka HM, Watzke H, Kralovics R, Gisslinger H.

Eur J Haematol. 2014 Aug;93(2):103-11. doi: 10.1111/ejh.12307. Epub 2014 Apr 23.

PMID:
24617727
7.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.

Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuk F, von Hünerbein N, Kvasnicka HM, Thiele J, Kreipe HH, Büsche G.

Biol Blood Marrow Transplant. 2014 Jun;20(6):812-5. doi: 10.1016/j.bbmt.2014.02.019. Epub 2014 Mar 1.

8.

Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin.

Evstatiev R, Bukaty A, Jimenez K, Kulnigg-Dabsch S, Surman L, Schmid W, Eferl R, Lippert K, Scheiber-Mojdehkar B, Kvasnicka HM, Khare V, Gasche C.

Am J Hematol. 2014 May;89(5):524-9. doi: 10.1002/ajh.23682. Epub 2014 Feb 24.

9.

WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Kvasnicka HM.

Curr Hematol Malig Rep. 2013 Dec;8(4):333-41. doi: 10.1007/s11899-013-0186-x. Review.

PMID:
24146204
10.

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group.

Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11.

11.

Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.

Reinart N, Nguyen PH, Boucas J, Rosen N, Kvasnicka HM, Heukamp L, Rudolph C, Ristovska V, Velmans T, Mueller C, Reiners KS, von Strandmann EP, Krause G, Montesinos-Rongen M, Schlegelberger B, Herling M, Hallek M, Fingerle-Rowson G.

Blood. 2013 Jan 31;121(5):812-21. doi: 10.1182/blood-2012-05-431452. Epub 2012 Nov 1.

12.

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up.

Ejerblad E, Kvasnicka HM, Thiele J, Andreasson B, Björkholm M, Löfvenberg E, Markevärn B, Merup M, Nilssson L, Palmblad J, Samuelsson J, Birgegård G.

Hematology. 2013 Jan;18(1):8-13. doi: 10.1179/1607845412Y.0000000023. Epub 2012 Sep 14.

PMID:
22990042
13.

A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.

Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, Kvasnicka HM, Ruggeri M, Randi ML, Gangat N, Vannucchi AM, Gianatti A, Gisslinger B, Müllauer L, Rodeghiero F, d'Amore ES, Bertozzi I, Hanson CA, Boveri E, Marino F, Maffioli M, Caramazza D, Antonioli E, Carrai V, Buxhofer-Ausch V, Pascutto C, Cazzola M, Barbui T, Tefferi A.

Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.

14.

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.

Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Müllauer L, Frantal S, Carobbio A, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Vannucchi AM, Antonioli E, Finazzi G, Gangat N, Tefferi A, Barbui T.

Am J Hematol. 2012 Jul;87(7):669-72. doi: 10.1002/ajh.23217. Epub 2012 May 10.

PMID:
22573503
15.

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment.

Thiele J, Orazi A, Kvasnicka HM, Franco V, Boveri E, Gianelli U, Gisslinger H, Passamonti F, Tefferi A, Barbui T.

Haematologica. 2012 Mar;97(3):e5-6; discussion e7-8. doi: 10.3324/haematol.2011.061432. No abstract available.

16.

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.

Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka HM, Büsche G, Ayuk F, Bacher U, Zander AR, Kröger N.

Br J Haematol. 2012 Apr;157(1):75-85. doi: 10.1111/j.1365-2141.2011.09009.x. Epub 2012 Jan 27.

PMID:
22280409
17.

Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.

Carobbio A, Finazzi G, Thiele J, Kvasnicka HM, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, Luigia Randi M, Bertozzi I, Vannucchi AM, Antonioli E, Gisslinger H, Buxhofer-Ausch V, Gangat N, Rambaldi A, Tefferi A, Barbui T.

Am J Hematol. 2012 Feb;87(2):203-4. doi: 10.1002/ajh.22241. Epub 2012 Jan 11.

PMID:
22237692
18.

Fluorescence in situ hybridization confirms the presence of Merkel cell polyomavirus in chronic lymphocytic leukemia cells.

Haugg AM, Speel EJ, Pantulu ND, Pallasch C, Kurz AK, Kvasnicka HM, Cathomas G, Wendtner CM, zur Hausen A.

Blood. 2011 May 26;117(21):5776-7. doi: 10.1182/blood-2011-03-339895. No abstract available.

19.

FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis.

Desterke C, Bilhou-Nabéra C, Guerton B, Martinaud C, Tonetti C, Clay D, Guglielmelli P, Vannucchi A, Bordessoule D, Hasselbalch H, Dupriez B, Benzoubir N, Bourgeade MF, Pierre-Louis O, Lazar V, Vainchenker W, Bennaceur-Griscelli A, Gisslinger H, Giraudier S, Le Bousse-Kerdilès MC; French Intergroup of Myeloproliferative Disorders,; French INSERM; European EUMNET Networks on Myelofibrosis.

Cancer Res. 2011 Apr 15;71(8):2901-15. doi: 10.1158/0008-5472.CAN-10-1731. Epub 2011 Apr 12. Erratum in: Cancer Res. 2011 Jun 1;71(11):4049-50.

20.

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.

Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H.

Blood. 2011 May 26;117(21):5710-8. doi: 10.1182/blood-2010-07-293761. Epub 2011 Mar 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk